Molecular Profile Detail

Profile Name NOTCH1 wild-type
Gene Variant Detail

NOTCH1 wild-type (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
NOTCH1 wild-type triple-receptor negative breast cancer no benefit MRK-003 + Paclitaxel Preclinical Actionable In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330). 25104330
NOTCH1 wild-type triple-receptor negative breast cancer decreased response MRK-003 Preclinical Actionable In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330). 25104330
Clinical Trial Phase Therapies Title Recruitment Status